Adamas Pharmaceuticals (NASDAQ:ADMS) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Thursday.

A number of other analysts also recently issued reports on ADMS. Cowen reaffirmed an “outperform” rating and set a $55.00 price target (up previously from $45.00) on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. JMP Securities reaffirmed an “outperform” rating and set a $33.00 price target (up previously from $29.00) on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. William Blair reaffirmed an “ourperform” rating on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $30.00 price target on shares of Adamas Pharmaceuticals in a report on Friday, September 1st. They noted that the move was a valuation call. Finally, ValuEngine raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. Adamas Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $42.00.

Shares of Adamas Pharmaceuticals (ADMS) opened at $33.35 on Thursday. The company has a current ratio of 8.35, a quick ratio of 8.32 and a debt-to-equity ratio of 0.41. Adamas Pharmaceuticals has a 1-year low of $13.50 and a 1-year high of $38.22.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.03). The business’s revenue was down 99.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.66) EPS. sell-side analysts forecast that Adamas Pharmaceuticals will post -3.84 earnings per share for the current year.

Large investors have recently modified their holdings of the company. SG Americas Securities LLC bought a new position in shares of Adamas Pharmaceuticals in the 3rd quarter worth approximately $110,000. Quantbot Technologies LP bought a new position in shares of Adamas Pharmaceuticals in the 3rd quarter worth approximately $119,000. Tower Research Capital LLC TRC bought a new position in shares of Adamas Pharmaceuticals in the 2nd quarter worth approximately $109,000. Sei Investments Co. lifted its stake in shares of Adamas Pharmaceuticals by 1,105.0% in the 3rd quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock worth $185,000 after purchasing an additional 8,033 shares during the period. Finally, Virtu KCG Holdings LLC bought a new position in shares of Adamas Pharmaceuticals in the 2nd quarter worth approximately $184,000. Hedge funds and other institutional investors own 79.45% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “BidaskClub Downgrades Adamas Pharmaceuticals (ADMS) to Hold” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/bidaskclub-downgrades-adamas-pharmaceuticals-adms-to-hold/1762401.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.